DMX-200 Phase 2a trial meets primary end point for Chronic Kidney Disease

DMX-200 is an adjunct therapy in which patients who are already on the standard of care angiotensin II type I receptor blocker (irbesartan) are also dosed with a chemokine receptor CCR2 blocker (propagermanium).

This Phase 2a trial was a dose escalation study in 27 patients with chronic kidney disease of a variety of causes. The primary end point was safety, with changes in biomarkers such as excess protein in the urine (proteinuria) as secondary end points. Proteinuria is a common symptom of kidney disease and is prognostic of deterioration of kidney function. High levels of protein in the urine also exacerbate the inflammation component of kidney disease, setting up a vicious cycle of disease progression.

The data released on the 12^th of July from the DMX-200 Phase 2a trial was that DMX-200 has demonstrated safety and tolerability in this diverse patient population, and that in some patient groups the clinically meaningful result of 50% reduction in proteinuria was seen. This reduction was over and above the best response the patients had achieved on the standard of care therapy.  These data provide the company with a wealth of information to design a more targeted Phase 2b efficacy study, and deepen engagement with potential licensing partners.

Request Information